📖 Your Q2 Earnings Guide: Discover the Stocks ProPicks AI Highlights to Jump Post-EarningsRead more

Boston Scientific to buy Silk Road Medical in $1.16 billion deal

Published 06/18/2024, 07:22 AM
Updated 06/18/2024, 11:02 AM
© Reuters.

By Sriparna Roy

(Reuters) -Boston Scientific will buy Silk Road Medical (NASDAQ:SILK) in a $1.16 billion deal, the company said on Tuesday, adding medical devices used for stroke prevention.

Boston, which generates most of its revenue from sales of heart devices such as pacemakers and stents, will pay $27.50 for each share of Silk Road held, representing a premium of 27% to the stock's last close.

Shares of Silk Road rose nearly 24% to $26.79 in premarket trading.

Silk Road's technology is used to prevent stroke in patients with carotid artery disease, a condition in which plaque builds up in the vessels that supply blood to the brain.

The minimally invasive procedure, called transcarotid artery revascularization (TCAR), temporarily reverses blood flow to divert the plaque build up away from the brain. A stent is then placed at the blockage site for plaque stabilization and future stroke prevention.

The deal follows Boston's $3.7 billion buyout of Axonics, which gave it access to devices used to improve bladder function. In April, the U.S. Federal Trade Commission requested additional information regarding the buyout.

At least three analysts said the Silk Road deal was complementary to Boston's portfolio.

The Massachussets-based company can help increase TCAR penetration within the U.S., launch new products, and expand into new markets such as Japan and China, said BTIG analyst Marie Thibault.

Boston Scientific (NYSE:BSX) expects to complete the transaction in the second half of 2024, after which Silk Road will operate as a wholly-owned unit. Silk Road has forecast net revenue of about $194 million to $198 million for this year.

The deal will have no material impact on its per share profit for this year and 2025, Boston Scientific said.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.